Biotech Values

[mcbio]

Taliglucerase, once approved, may win at least 15 percent of patients “through strong marketing and competitive pricing,” said Ritu Baral, an analyst at Canaccord Genuity in New York, in a Feb. 22 note to clients.

Is 15% of the market really the consensus expected peak potential for this drug? I would think PFE wouldn't have bothered to get involved if they were only forecasting peak potential of 15% market share, especially since they will only be getting 60% of revenues.